<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845520</url>
  </required_header>
  <id_info>
    <org_study_id>CSP 002-00</org_study_id>
    <nct_id>NCT00845520</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the Calhoun Vision Light Adjustable Intraocular Lens (LAL)</brief_title>
  <official_title>A Prospective Multi-center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects Undergoing Cataract Extraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calhoun Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calhoun Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate, for the visual correction of aphakia, the
      safety and effectiveness of the Calhoun Vision Light Adjustable intraocular lens (LAL) and
      Light Delivery Device (LDD) in treating postoperative residual refractive error by providing
      a stable, targeted refractive adjustment of the LAL power and lock-in treatments with the
      LDD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2 medical device study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Eyes Achieving a Manifest Refraction Spherical Equivalent (MRSE) Within ± 0.50 D of the Intended Adjustment Target</measure>
    <time_frame>6 months post-operative</time_frame>
    <description>Predictability of post-operative refractive adjustments of the implanted LAL, with 75% of the eyes achieving a manifest refraction spherical equivalent (MRSE) within ± 0.50 D of the intended adjustment target at the point of stability. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Eyes With Improvement in Uncorrected Visual Acuity (UCVA)</measure>
    <time_frame>6 months post operative</time_frame>
    <description>Improvement in uncorrected visual acuity (UCVA): For those best case eyes with a pre-light treatment UCVA of 20/50 or worse, 65% of eyes should have an uncorrected visual acuity of 20/40 or better at the refractive stable point after the adjustment and lock-in treatments. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Best Corrected Visual Acuity (BSCVA) of 20/40 or Better</measure>
    <time_frame>12 months</time_frame>
    <description>Best Corrected Visual Acuity (BSCVA): The percentage of eyes achieving overall and best case BSCVA of 20/40 or better should be comparable to the FDA grid of historical controls for intraocular lenses. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>Lens implantation +1.00 diopter (D) postop target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lens implant power calculated for postoperative MRSE target of +1.00 D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens implantation -1.00 D postop target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lens implant power calculated for postoperative MRSE target of -1.00 D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lens implantation 0.00 D postop target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lens implant power calculated for postoperative MRSE target of 0.00 D</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens implantation +1.00 D postop target</intervention_name>
    <description>Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.</description>
    <arm_group_label>Lens implantation +1.00 diopter (D) postop target</arm_group_label>
    <other_name>Light Delivery Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens implantation -1.00 D postop target</intervention_name>
    <description>Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.</description>
    <arm_group_label>Lens implantation -1.00 D postop target</arm_group_label>
    <other_name>Light Delivery Device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lens implantation 0.00 D postop target</intervention_name>
    <description>Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.</description>
    <arm_group_label>Lens implantation 0.00 D postop target</arm_group_label>
    <other_name>Light Delivery Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-operative regular corneal astigmatism less than or equal to 1.00 diopters by
             keratometry.

          -  Adults between the ages of 40 and 80 inclusive.

          -  Cataract causing reduction in best spectacle-corrected visual acuity to a level of
             20/32 or worse.

          -  Best corrected visual acuity projected (by clinical estimate based upon past ocular
             history and retinal exam) to be 20/25 or better after cataract removal and IOL
             implantation.

          -  Clear intraocular media other than cataract.

          -  Potentially good vision in the fellow eye with BCVA 20/40 or better.

          -  Willing and able to comply with the schedule for power adjustment/lock-in treatments
             and the schedule for follow-up visits.

          -  Fully dilated pupil diameter of more than or equal to 7.0 mm.

        Exclusion Criteria:

          -  Zonular laxity or dehiscence.

          -  Pseudoexfoliation.

          -  Age related macular degeneration involving the presence of geographic atrophy or soft
             drusen.

          -  Retinal degenerative disorder that is expected to cause future vision loss.

          -  Diabetes with any evidence of retinopathy.

          -  Evidence of glaucomatous optic neuropathy.

          -  History of uveitis.

          -  Significant anterior segment pathology, such as rubeosis iridis, aniridia, or iris
             coloboma.

          -  Corneal pathology that is either progressive or sufficient to reduce BCVA to 20/25 or
             worse.

          -  Keratoconus or suspected of having keratoconus.

          -  Corneal dystrophy including basement membrane dystrophy.

          -  Previous corneal or intraocular surgery

          -  Systemic medication that may increase sensitivity to UV light such as tetracycline,
             doxycycline, psoralens, amiodarone, and phenothiazines.

          -  Complications during cataract surgery including posterior capsule rupture, zonular
             rupture, radial capsulorhexis tear, vitreous loss, iris trauma, corneal complications
             or any intraoperative abnormality that may affect the postoperative pupillary
             dilation, or the centration or tilt of the intraocular lens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Doyle Stulting, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altos Eye Physicians</name>
      <address>
        <city>Los Altos</city>
        <state>California</state>
        <zip>94024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maloney Vision Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pepose Vision Institute</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CODET Vision Institute</name>
      <address>
        <city>Tijuana</city>
        <state>Zona Rio</state>
        <zip>22320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <results_first_submitted>December 28, 2017</results_first_submitted>
  <results_first_submitted_qc>June 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2018</results_first_posted>
  <last_update_submitted>June 6, 2018</last_update_submitted>
  <last_update_submitted_qc>June 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lens Implant Power +1.00 D Target</title>
          <description>Lens implant power +1.00 D target: Subjects who require cataract extraction and intraocular lens implantation are implanted with the Light Adjustable Lens with a postoperative +1.00 D MRSE target. At 17 to 21 days, the manifest refraction is measured and the implanted LAL is treated with a targeted dose of light using the Light Delivery Device to produce a modification in the lens curvature, resulting in a predictable change in refractive power.</description>
        </group>
        <group group_id="P2">
          <title>Lens Implant Power -1.00 D Target</title>
          <description>Lens implant power -1.00 D target: Subjects who require cataract extraction and intraocular lens implantation are implanted with the Light Adjustable Lens with a postoperative -1.00 D MRSE target. At 17 to 21 days, the manifest refraction is measured and the implanted LAL is treated with a targeted dose of light using the Light Delivery Device to produce a modification in the lens curvature, resulting in a predictable change in refractive power.</description>
        </group>
        <group group_id="P3">
          <title>Lens Implant Power 0.00 D Target</title>
          <description>Lens implant power 0.00 D target: Subjects who require cataract extraction and intraocular lens implantation are implanted with the Light Adjustable Lens with a postoperative 0.00 D MRSE target. At 17 to 21 days, the manifest refraction is measured and the implanted LAL is treated with a targeted dose of light using the Light Delivery Device to produce a modification in the lens curvature, resulting in a predictable change in refractive power.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lens Implant Power +1.00 D Target</title>
          <description>The eyes would have a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of +1.00 diopter</description>
        </group>
        <group group_id="B2">
          <title>Lens Implant Power 0.00 D Target</title>
          <description>The eyes would have a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of 0.00 diopter</description>
        </group>
        <group group_id="B3">
          <title>Lens Implant Power -1.00 D Target</title>
          <description>The eyes would have a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of 11.00 diopter</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" spread="9.3"/>
                    <measurement group_id="B2" value="65.6" spread="7.3"/>
                    <measurement group_id="B3" value="65.9" spread="9.2"/>
                    <measurement group_id="B4" value="66.1" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes Achieving a Manifest Refraction Spherical Equivalent (MRSE) Within ± 0.50 D of the Intended Adjustment Target</title>
        <description>Predictability of post-operative refractive adjustments of the implanted LAL, with 75% of the eyes achieving a manifest refraction spherical equivalent (MRSE) within ± 0.50 D of the intended adjustment target at the point of stability. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
        <time_frame>6 months post-operative</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Lens Implant Power -1.00 D Target</title>
            <description>Eyes randomized to a target lens implant power of -1.00 D</description>
          </group>
          <group group_id="O2">
            <title>Lens Implant Power +1.00 D Target</title>
            <description>Eyes randomized to a target lens implant power of +1.00 D</description>
          </group>
          <group group_id="O3">
            <title>Lens Implant Power 0.00 D Target</title>
            <description>Eyes randomized to a target lens implant power of 0.00 D</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes Achieving a Manifest Refraction Spherical Equivalent (MRSE) Within ± 0.50 D of the Intended Adjustment Target</title>
          <description>Predictability of post-operative refractive adjustments of the implanted LAL, with 75% of the eyes achieving a manifest refraction spherical equivalent (MRSE) within ± 0.50 D of the intended adjustment target at the point of stability. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
          <population>ITT</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Eyes With Improvement in Uncorrected Visual Acuity (UCVA)</title>
        <description>Improvement in uncorrected visual acuity (UCVA): For those best case eyes with a pre-light treatment UCVA of 20/50 or worse, 65% of eyes should have an uncorrected visual acuity of 20/40 or better at the refractive stable point after the adjustment and lock-in treatments. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
        <time_frame>6 months post operative</time_frame>
        <population>Participants with eyes with UCVA of 20/50 or worse UCVA prior to light treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Lens Implant Power -1.00 D Target</title>
            <description>Eyes randomized to a target of -1.00 D</description>
          </group>
          <group group_id="O2">
            <title>Lens Implant Power of +1.00 D</title>
            <description>Eyes randomized to a target of +1.00 D</description>
          </group>
          <group group_id="O3">
            <title>Lens Implant Power of 0.0 D Target</title>
            <description>Eyes randomized to a target of 0.0 D</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Eyes With Improvement in Uncorrected Visual Acuity (UCVA)</title>
          <description>Improvement in uncorrected visual acuity (UCVA): For those best case eyes with a pre-light treatment UCVA of 20/50 or worse, 65% of eyes should have an uncorrected visual acuity of 20/40 or better at the refractive stable point after the adjustment and lock-in treatments. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
          <population>Participants with eyes with UCVA of 20/50 or worse UCVA prior to light treatment</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Best Corrected Visual Acuity (BSCVA) of 20/40 or Better</title>
        <description>Best Corrected Visual Acuity (BSCVA): The percentage of eyes achieving overall and best case BSCVA of 20/40 or better should be comparable to the FDA grid of historical controls for intraocular lenses. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
        <time_frame>12 months</time_frame>
        <population>All available eyes at 12 months. The overall number of participants for this outcome measures differs the previously stated overall number of 74 because two subjects were deceased at their 12 month post-operative follow up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Lens Implant Power With -1.00 D Target</title>
            <description>Eyes randomized to a postoperative target MRSE of -1.00 D</description>
          </group>
          <group group_id="O2">
            <title>Lens Implant Power With 0.00 D Target</title>
            <description>Eyes randomized to a postoperative target MRSE of 0.00 D</description>
          </group>
          <group group_id="O3">
            <title>Lens Implant Power With +1.00 D Target</title>
            <description>Eyes randomized to a postoperative target MRSE of +1.00 D</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Best Corrected Visual Acuity (BSCVA) of 20/40 or Better</title>
          <description>Best Corrected Visual Acuity (BSCVA): The percentage of eyes achieving overall and best case BSCVA of 20/40 or better should be comparable to the FDA grid of historical controls for intraocular lenses. All three arms of the study had the same end point so the results were presented as one combined cohort.</description>
          <population>All available eyes at 12 months. The overall number of participants for this outcome measures differs the previously stated overall number of 74 because two subjects were deceased at their 12 month post-operative follow up visit.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lens Implant Power of +1.00 D Target</title>
          <description>Eyes with a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of +1.00 D</description>
        </group>
        <group group_id="E2">
          <title>Lens Implant Power of -1.00 D Target</title>
          <description>Eyes with a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of -1.00 D</description>
        </group>
        <group group_id="E3">
          <title>Lens Implant Power of 0.00 D</title>
          <description>Eyes with a post-surgical Manifest Refraction Spherical Equivalent (MRSE) target of 0.00 D</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>heart attack with pacemaker implanted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>epiretinal membrane and macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>wet age related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>macular edema secondary to epiretinal membrate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior Capsular Opacity</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E2" events="37" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" events="30" subjects_affected="13" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maureen O'Connell Vice President, Regulator and Clinical Affairs</name_or_title>
      <organization>RxSight, Inc.</organization>
      <phone>978-207-12415</phone>
      <email>moconnell@rxsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

